US-based oncology software company Massive Bio has launched Patient Connect, a free portal that aims to personalise access to cancer clinical trials worldwide.
The platform uses AI to match patients with suitable clinical trials based on their medical profiles.
Go deeper with GlobalData
Patient Connect is designed to empower cancer patients by simplifying their search for appropriate clinical trials.
Patients can provide consented access to their medical records and make use of Massive Bio’s AI-powered system to identify the most relevant clinical trial options.
The portal supports multiple languages to encourage broad accessibility and personalised care.
Patient Connect allows more than 132,000 patients onboarded by Massive Bio to access their personal clinical trial matches from nearly 16,000 trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataMassive Bio chief medical officer and co-founder Dr Arturo Loaiza-Bonilla said: “Patient Connect redefines how patients engage with clinical trials, offering them a lifeline to new treatment possibilities and hope for better outcomes.“
In addition to the AI platform, Massive Bio provides personalised support through its concierge services, which aim to ensure a smooth transition from referral to trial participation.
The company also works with oncologists and haematologists through the Massive Bio Clinical Network, which allows treating physicians to review pre-screening results and oversee their patients’ enrolment in clinical trials.
Massive Bio chief product officer Oz Hüner said: “Patient Connect empowers people to intuitively navigate the clinical trial enrolment process, keeping patients connected to their physicians and loved ones throughout their personal journey.”
Earlier this year, Massive Bio entered an expanded partnership with clinical trial search platform Un Ensayo Para Mi (UEPM) to enhance access to oncology clinical trials in Latin America.
The companies will deploy advanced AI technologies across nine Latin American countries to improve clinical trial availability and patient care.
